Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer

Table 6 Recurrences and death

Overall	Weekly docetaxel (n = 41)		3-weekly docetaxel (n = 41)		P-value
	No.	%	No.	%
Recurrence	10	24	11	27	0.80
Locoregional	4	10	3	7	1.00
Contralateral	0	0	2	5	0.49
Distant	10	24	8	20	0.59
Death	8	20	6	15	0.49

ISSN: 1471-2407